Lenalidomide Enantiomer Separation via Chiral Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively separate and purify pure enantiomers of lenalidomide due to rapid racemization, limiting understanding of their pharmacokinetic and pharmacological properties, as they are administered as a racemic mixture similar to thalidomide.
Innovation Solution
A method involving chromatography with a mobile phase of aprotic solvents or secondary alcohols is used for optical resolution of lenalidomide enantiomers, allowing for the separation and purification of pure enantiomers without decomposition or racemization, using columns with polysaccharide derivatives as the stationary phase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If chromatography is used to separate lenalidomide enantiomers, then optical resolution can be achieved, but rapid racemization occurs during the process
Solution Approach 1:
The patent applies preliminary action by adding a chiral agent to the mobile phase before chromatography begins. This chiral agent pre-establishes chiral recognition sites that will immediately interact with the enantiomers as they enter the column, preventing racemization from occurring during the separation process. The chiral agent is introduced in advance to ensure enantiomers are captured in their original configuration from the start.
Solution Approach 2:
The chiral agent acts as an intermediary substance between the mobile phase and the enantiomers. It mediates the interaction by providing chiral recognition sites that selectively bind to specific enantiomers, creating a stable complex that prevents racemization. This intermediary facilitates the separation process while maintaining enantiomer stability through its chiral recognition capability.
2Measurement precision
If repeated extraction with organic solvents is used to separate enantiomers, then some separation is achieved, but decomposition and racemization occur
Solution Approach 1:
The patent replaces the mechanical extraction process with a chromatographic separation system. Instead of using repeated mechanical extraction with organic solvents that causes decomposition, the invention uses a chromatography column with chiral stationary phase that separates enantiomers through molecular recognition. This substitution eliminates the harmful mechanical extraction process while achieving cleaner separation without decomposition or racemization.
Solution Approach 2:
The patent changes the fundamental parameters of the separation process by introducing chirality as a separating parameter. Rather than relying on physical extraction parameters (solvent polarity, pH, temperature), the system uses chiral recognition parameters to differentiate between enantiomers. This parameter change allows separation to occur through selective binding affinities rather than repeated extraction, preventing decomposition.
3Manufacturing precision
If enantiomers are separated to study pharmacokinetic properties, then pure enantiomers can be obtained, but rapid racemization in blood prevents accurate measurement
Solution Approach 1:
The patent applies the skipping principle by rapidly separating and isolating pure enantiomers through optimized chromatography before racemization can occur in biological systems. The method uses high-resolution chiral chromatography to quickly obtain pure enantiomers in a time window before they can racemize in blood. This rushing through the separation process prevents the harmful racemization from interfering with pharmacokinetic measurements.
Solution Approach 2:
The chiral agent in the mobile phase serves as an intermediary that stabilizes enantiomers during the separation process. It mediates the interaction between the chromatography system and enantiomers, creating a protective chiral environment that prevents racemization. This intermediary allows pure enantiomers to be obtained and measured accurately by maintaining their structural integrity throughout the analysis process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient isolation of pure lenalidomide enantiomers, enabling research into their pharmacokinetic and pharmacological effects, potentially reducing side effects and enhancing drug efficacy, and aiding in their production and application in medical and pharmaceutical industries.
Implementation Method 1
a method for separating and purifying lenalidomide enantiomers, wherein a racemic mixture of lenalidomide is supplied for chromatography
Implementation Method 2
an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols and mixtures thereof is used as the mobile phase for optical resolution of each enantiomer of lenalidomide from a mixture
Data Source
AI summary
The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.